Allianz Asset Management GmbH Purchases 10,600 Shares of Sanofi (NASDAQ:SNY)

Allianz Asset Management GmbH raised its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 33.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 42,000 shares of the company's stock after purchasing an additional 10,600 shares during the quarter. Allianz Asset Management GmbH's holdings in Sanofi were worth $2,329,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Cardinal Capital Management boosted its position in shares of Sanofi by 0.3% in the first quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock worth $3,827,000 after buying an additional 199 shares during the period. Gradient Investments LLC raised its holdings in Sanofi by 2.1% during the first quarter. Gradient Investments LLC now owns 9,764 shares of the company's stock valued at $542,000 after buying an additional 200 shares in the last quarter. Perigon Wealth Management LLC raised its position in shares of Sanofi by 3.1% in the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock valued at $367,000 after purchasing an additional 201 shares during the period. Beacon Financial Group lifted its position in Sanofi by 1.6% during the 1st quarter. Beacon Financial Group now owns 14,398 shares of the company's stock worth $799,000 after acquiring an additional 222 shares during the last quarter. Finally, AdvisorNet Financial Inc lifted its position in shares of Sanofi by 16.4% during the 1st quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company's stock worth $89,000 after purchasing an additional 227 shares during the last quarter. 14.04% of the stock is owned by institutional investors.

Sanofi Trading Up 2.4%

SNY traded up $1.11 during midday trading on Friday, reaching $46.75. 2,518,877 shares of the company were exchanged, compared to its average volume of 2,122,035. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. Sanofi has a one year low of $44.73 and a one year high of $60.12. The stock has a market capitalization of $114.65 billion, a P/E ratio of 11.10, a PEG ratio of 1.05 and a beta of 0.48. The stock's 50-day simple moving average is $49.21 and its 200 day simple moving average is $52.09.

Wall Street Analysts Forecast Growth

SNY has been the subject of several recent analyst reports. Guggenheim restated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Morgan Stanley set a $56.00 price objective on Sanofi in a report on Monday, June 2nd. Barclays restated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Finally, BNP Paribas started coverage on shares of Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $62.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.